Key result
Antithrombin supplementation has theoretical and observational support for suppressing ECMO circuit thrombosis in sepsis, but definitive randomized controlled trials are lacking to confirm its efficacy.
Why the study?
Circuit thrombosis remains a significant complication during ECMO in severe sepsis despite heparin, and low antithrombin levels raise concerns regarding heparin efficacy.
Does antithrombin supplementation prevent ECMO circuit thrombosis in septic patients?
Does antithrombin supplementation prevent ECMO circuit thrombosis in septic patients?
Current evidence suggests a potential benefit of antithrombin supplementation for preventing ECMO circuit thrombosis in sepsis, but high-quality randomized trials are required to establish definitive clinical guidelines.
Should not yet change practice in septic ECMO anticoagulation; leaves open AT supplementation's effect on circuit thrombosis.
Extracorporeal membrane oxygenation (ECMO) is increasingly used for the management of severe sepsis-induced cardiopulmonary failure. Despite standard heparin anticoagulation, circuit thrombosis remains a significant complication. Antithrombin (AT), a critical serine protease inhibitor and cofactor for heparin, is often low in septic patients, especially during ECMO, raising concerns about the efficacy of heparin-based anticoagulation. This review explores the role of AT supplementation to suppress ECMO circuit thrombosis in sepsis, integrating epidemiological data, underlying pathophysiology, preclinical research, and clinical evidence. While theoretical rationale and some observational data support the supplementation of AT, definitive clinical trials are lacking. We conclude by outlining future perspectives and research needs to clarify the role of AT in ECMO management for septic patients.
No takes yet. Share an insight, caveat, or question.
Levy et al. (2025) conducted a review in Sepsis requiring extracorporeal membrane oxygenation (ECMO). Antithrombin supplementation vs. Standard heparin anticoagulation was evaluated. Antithrombin supplementation has theoretical and observational support for suppressing ECMO circuit thrombosis in sepsis, but definitive randomized controlled trials are lacking to confirm its efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: